Compare Viatris Inc (VTRS) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Wells Fargo & Co — how do they compare? Viatris Inc trades at $17.35 (market cap $20.03B), while Wells Fargo & Co trades at $82.15 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 12.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Wells Fargo & Co for 87 Days on average.
| VTRS | WFC | |
|---|---|---|
Market Cap | $20.03B | $248.06B |
Volume | 14,109,977 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $18.27 | $96.40 |
52-Week Low | $9.74 | $73.42 |
Typical Hold Time | 57 Days | 87 Days |
Enterprise Value | $32.15B | $503.91B |
Dividend Yield | 2.75% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Wells Fargo (WFC) trades at $80.26, down 1.53% today, with a bearish technical signal despite recent earnings beat in Q2 2026. The company shows strong fundamentals with a P/E of 11.92, net income margin of 25.97%, and a recent credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01). Revenue growth is steady, reaching $83.70B in 2025, with a consensus price target of $99.13 suggesting upside potential.
The stock presents a value opportunity with attractive valuation metrics and improving profitability, but faces risks from volatile cash flows and regulatory changes in bank stress tests. Analyst sentiment is mixed with 46.66% buy ratings, while technical indicators signal near-term caution. Upside hinges on Q3 2026 earnings meeting expectations of $1.85 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
